... bisphosphonate, ibandronate, has been shown to reduce the risk of skeletal events after oral or intravenous administration in controlled clinical trials in various malignancies, and to confer significant palliation of bone pain and improvements in health-related quality of life in patients with metastatic breast...

...Kadri Altundag; Omer Dizdar; Zeynep Ozsaran; Serdar Ozkok; Pinar Saip; Yesim Eralp; Seref Komurcu; Okan Kuzhan; Mustafa Ozguroglu; Metin Karahoca Background: The aim of this study was to determine the efficacy and safety of loading-dose intravenous (i.v.) ibandronate in women with breast cancer...

...Roger von Moos; Clemens B. Caspar; Rolf Steiner; Rahel Angst; Roman Inauen; Kerstin Schmieding; Beat Thürlimann Background: In an earlier study, intravenous (i.v.) ibandronate 6 mg administered every 3–4 weeks had a similarly good renal safety profile whether infused over 15 or 60 min in women...

... bisphosphonate, which is an elementary part of the standard therapeutic regimen of MM. Patients and Methods: We evaluated the tolerability of ibandronate 2–6 mg every 4 weeks in patients with MM and ESRD receiving regular hemodialysis over 12 weeks (open-label, single-center, observational study). Ibandronate...

...F. Bauss Ibandronate is an aminobisphosphonate that targets bone and inhibits osteoclasts. It is one of the most potent bisphosphonates currently under clinical investigation in metabolic bone disease and osteoporosis. In animal models ibandronate is 2, 10, 50 and 500 times more potent than...